Pulmonary Fibrosis — Clinical Documentation Guide (2026)

🔍 Definition

Pulmonary fibrosis is a chronic, progressive, and ultimately fatal interstitial lung disease (ILD) characterized by the pathological accumulation of fibrotic scar tissue within the pulmonary parenchyma. The fibrotic process replaces normal alveolar architecture with dense connective tissue, resulting in irreversible loss of lung compliance and impaired gas exchange. The umbrella term encompasses a heterogeneous group of more than 200 distinct ILD subtypes, ranging from well-defined entities such as idiopathic pulmonary fibrosis (IPF) to secondary fibrotic processes arising from connective tissue diseases, occupational exposures, hypersensitivity pneumonitis, and drug toxicity.

For ICD-10-CM coding purposes under FY2026 Official Guidelines, pulmonary fibrosis codes reside primarily in category J84 – Other interstitial pulmonary diseases, with closely related conditions coded across J60–J70 (pneumoconioses and occupational lung diseases), D86 (sarcoidosis), and J80 (acute respiratory distress syndrome). Selecting the most specific code within J84 is paramount for accurate HCC risk adjustment and MS-DRG assignment.

🗂️ Alternative Terminology

The clinical and lay terminology for pulmonary fibrosis is highly variable. Coders must map colloquial documentation to the correct ICD-10-CM subcategory.

🩺 Signs & Symptoms

Pulmonary fibrosis presents insidiously; symptoms are often attributed to other conditions (deconditioning, cardiac disease) for months to years before diagnosis. Key clinical features include:

• Progressive exertional dyspnea — the cardinal symptom, initially on exertion and advancing to rest in severe disease
• Dry, nonproductive cough — persistent and often refractory to standard antitussives
• Bibasilar inspiratory crackles ("Velcro" crackles) — present in ~80% of IPF patients on auscultation
• Digital clubbing — present in up to 50% of IPF cases; less common in other ILD subtypes
• Hypoxemia — exertional desaturation (SaO₂ <90% on 6-minute walk test) and resting hypoxemia in advanced disease
• Reduced exercise tolerance — 6-minute walk distance (6MWD) is a validated outcome measure per ATS/ERS/JRS/ALAT IPF guidelines
• Weight loss and fatigue — systemic manifestations in progressive disease
• Signs of pulmonary hypertension — elevated JVP, right ventricular heave, loud P2 in advanced fibrosis (code separately with I27.2x)
• Acute exacerbation of IPF (AE-IPF) — rapid respiratory deterioration with new bilateral ground-glass opacities superimposed on UIP background; high mortality

🧭 Differential Diagnosis

Establishing the correct ILD subtype requires multidisciplinary discussion (MDD) integrating clinical history, HRCT pattern, BAL findings, and—when performed—surgical lung biopsy results. The following differential diagnoses are relevant for coding and CDI purposes.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators, when present in the medical record, support specific ICD-10-CM code assignment and justify higher-specificity reporting:

🦴 Anatomy & Pathophysiology

Pulmonary fibrosis results from aberrant wound healing within the lung parenchyma. Under normal circumstances, alveolar epithelial injury triggers a regulated repair cascade involving type II pneumocytes, fibroblasts, and myofibroblasts. In pathological fibrosis, this process becomes dysregulated and self-perpetuating.

Normal Lung Anatomy Relevant to ILD

The lung's gas-exchanging unit — the alveolus — is lined by type I pneumocytes (thin, covering ~95% of the surface for gas exchange) and type II pneumocytes (cuboidal, producing surfactant). The alveolar interstitium contains capillary endothelium, fibroblasts, mast cells, macrophages, and a minimal extracellular matrix. In health, the interstitium is barely visible on imaging.

Pathological Mechanisms in IPF

The current paradigm frames IPF as an epithelial-driven fibrotic disease. Repeated microinjuries (from gastric aspiration, viral infection, particulates, or genetic predisposition in carriers of MUC5B or TERT/TERC telomere gene variants) cause type II pneumocyte apoptosis and senescence. This releases profibrotic mediators — TGF-β1, CTGF, PDGF — that activate resident fibroblasts and circulating fibrocytes to differentiate into myofibroblasts. Myofibroblasts deposit excessive collagen I and III, and fail to undergo apoptosis, resulting in the progressive accumulation of fibrotic foci seen histologically in UIP.

Histopathological Patterns

• UIP (Usual Interstitial Pneumonia): Temporal heterogeneity with fibroblastic foci, dense fibrosis, honeycombing, architectural distortion; subpleural and basal predominance. Correlates with J84.112 when idiopathic.
• NSIP (Nonspecific Interstitial Pneumonia): Temporally homogeneous fibrosis or ground-glass opacity; less honeycombing; better prognosis. Idiopathic form → J84.113; CTD-associated → J99 with primary CTD code first.
• DIP (Desquamative Interstitial Pneumonia): Diffuse alveolar macrophage accumulation; strongly associated with smoking → J84.117.
• RB-ILD: Respiratory bronchiolitis with peribronchiolar macrophage accumulation → J84.115.
• COP (Cryptogenic Organizing Pneumonia): Intraluminal fibroblastic plugs (Masson bodies) filling alveolar ducts and alveoli → J84.116.

Functional Consequences

Progressive fibrosis reduces lung compliance, causing a restrictive ventilatory defect (reduced FVC, reduced TLC). Thickening of the alveolar-capillary membrane impairs diffusion of oxygen (reduced DLCO/KCO). Hypoxemia worsens with exertion first, then occurs at rest in severe disease. Fibrosis-associated pulmonary hypertension (Group 3 PH) develops in 30–40% of advanced IPF patients and worsens prognosis significantly (code I27.22 or I27.29 separately).

💊 Medication Impact / Treatment

Pharmacological management of pulmonary fibrosis is primarily aimed at slowing disease progression rather than reversing established fibrosis. Two antifibrotic agents are FDA-approved for IPF; nintedanib has also received approval for systemic sclerosis-ILD and progressive pulmonary fibrosis (which encompasses J84.170).

Antifibrotic Agents (Impact on Coding & Documentation)

• Nintedanib (Ofev®): Tyrosine kinase inhibitor targeting PDGFR, FGFR, and VEGFR; approved for IPF (J84.112), SSc-ILD (M34.81 + J99), and progressive pulmonary fibrosis (J84.170). HCPCS J7686 for injectable formulation; oral formulation typically billed via NDC for Medicare Part D. Presence in the medication record is a strong CDI indicator supporting J84.112 or J84.170 coding.
• Pirfenidone (Esbriet®): Antifibrotic and anti-inflammatory; approved for IPF. HCPCS J3490 (unlisted drug) when not otherwise specified; billed via NDC for Medicare Part D oral administration. Presence supports J84.112 assignment.

Supportive Therapies

• Supplemental oxygen: Prescribed for resting SaO₂ ≤88% or exertional desaturation. HCPCS E1390 (stationary O₂ concentrator), E0433 (portable liquid O₂ system). Document Z99.81 (dependence on supplemental oxygen) when chronic O₂ >15 hr/day — critical for RAF and quality measures.
• Pulmonary rehabilitation: CPT 94005, G0424; improves exercise capacity and quality of life in ILD.
• Lung transplantation: Definitive therapy for eligible patients; coding shifts to post-transplant ICD-10-CM codes (Z94.2, T86.81x); bilateral single-lung transplant most common for IPF.
• Immunosuppression for CTD-ILD: Mycophenolate mofetil, azathioprine, rituximab for SSc-ILD or RA-ILD; document underlying CTD and lung manifestation.
• Systemic corticosteroids: Used for COP (J84.116), DIP (J84.117), LIP (J84.2), acute exacerbation of IPF; NOT recommended for stable IPF (can increase mortality per ATS/ERS IPF Guidelines).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides